Abstract
1. nRichDX Launches Two New Products for Liquid Biopsy Applications
nRichDX® has launched two new products designed to help researchers advance liquid biopsy assay development. Both products are designed for use with nRichDX's Revolution Sample Prep System™.
nRichDX's Revolution Sample Prep System is currently used by researchers for the high-yield extraction of rare cfDNA from 1ml – 20ml of either plasma or urine samples. cfDNA is currently the principal analyte used for a variety of liquid biopsy assays and detection methods.
cfRNA is increasingly being used to develop liquid biopsy applications. Researchers will now be able to use their Revolution Sample Prep Systems to achieve higher yields of total nucleic acid and cfRNA from plasma and urine.
nRichDX's second new product, the cfDNA Reference Standard, is based on mono-nucleosomal DNA and is an established standard used by researchers and liquid biopsy assay developers. The new product contains tubes of thaw-and-use cfDNA extraction controls to measure the yield and efficiency of cfDNA extraction..
2. Complete Genomics, part of MGI, Announce launch of DNBSEQ - G400
Complete Genomics offers complete NGS instrumentation and related products, including sample extraction, library prep, automation system, sequencing platforms, and bioinformatics. Though new to the US market, MGI has been providing NGS sequencers since 2017 and has more than thousands of sequencers installed around the world. MGI redefines sequencing possibilities through its latest innovation, DNBSEQTM. This technology is available on all sequencing platforms, which eliminates index hopping and clonal errors during the sequencing step of NGS workflow. This process makes sequencing much more accurate, flexible, and affordable, resulting in enhanced sequencing capacities and accelerated scientific breakthroughs for researchers. Complete Genomics released their DNBSEQ-G400* sequencers in the US in August and placed the first few instruments in customers' labs within a week. DNBSEQ-G400* is a day-to-day, medium throughput (data output up to 1440Gb daily) benchtop sequencer that offers extensive options for researchers. DNBSEQ-G400* has the option to run 1 or 2 flow cells with 2 types of flow cells (550M/reads vs 1800M/reads) and various read length options from SE50 to SE400 or PE300.
3. Foundation Medicine Launches Foundation-Report+™, a New Digital Reporting Experience to Streamline Precision Cancer Care
A pioneer in molecular profiling for cancer, launch Foundation-Report+, a new interactive digital report to enhance the useability of comprehensive genomic profiling (CGP) results. The digital view of the Foundation Medicine report provides physicians with an adaptable experience to view genomic insights and supports more efficient and streamlined treatment decisions for their patients.
Accessible through the Foundation Medicine online portal, the new digital reporting tool is customizable to each user's preference and allows healthcare providers to control the depth of information they would like to see within the digital reporting experience. With improved navigation to actionable insights, the interactive functionality improves overall clarity of patients' results compared to the traditional PDF report.
4. Nucleai Launches New Multiplex Imaging Spatial Analysis Solution to Increase Reliability and Speed of Immunofluorescence Analysis for Drug Discovery and Development
Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development.
While mIF is a powerful technology for cancer research, current tools for mIF image analysis are time-consuming, manual, and not robust enough to generalize across different platforms, markers and indications. Nucleai addresses these challenges, bringing 40% improvement in accuracy compared to other solutions, while also reducing mIF analysis time-to-results from months to only weeks. Nucleai's mIF pipeline, built and trained on millions of annotations across different staining platforms, indications and markers, provides the most comprehensive mIF deep-learning based solution available on market today.
Contact us at